Guess which ASX All Ords share is crashing 30% today

Investors have been hitting the sell button in a panic on Friday.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Integral Diagnostics Ltd (ASX: IDX) share price is having a day to forget on Friday.

At the time of writing, the ASX All Ords share is down 30% to $1.86.

A man sitting at a computer is blown away by what he's seeing on the screen, hair and tie whooshing back as he screams argh in panic.

Image source: Getty Images

Why is this ASX All Ords share crashing?

Investors have been scrambling to the exits today after the medical imaging services provider released a very disappointing trading update.

According to the release, first-quarter revenue growth of 8.4% was achieved in Australia compared with the prior corresponding period.

As a comparison, management highlights that Medicare benefits for the states in which Integral Diagnostics operates have seen a 9.5% increase in the weighted average benefits paid, adjusted for working days.

Over in New Zealand, the company achieved a 4.1% increase in constant currency revenue compared with the prior corresponding period.

However, this growth appears to have been offset by higher-than-expected labour costs which have impacted its operating EBITDA. This has been driven by clinical staff shortages, particularly in regional areas, and cost inflation.

In light of this, the ASX All Ords share has not seen the expected operating EBITDA margin improvement it was expecting.

Management advised that it is responding to these pressures by accelerating productivity and efficiency initiatives. These actions are expected to lead to an improvement in its margin performance in the second half.

The company hasn't provided any earnings guidance for the half (or full year) but has given investors an idea of what to expect in respect to capex, depreciation, and finance costs.

Replacement and growth capex is to be in the range of $30 million to $40 million in FY 2024. Whereas depreciation of ~$45 million and finance costs of ~$22 million are forecast for the 12 months. The latter assumes that the Reserve Bank will increase rates by a further 0.25% next week.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Integral Diagnostics. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Broker sees 26% upside in ASX healthcare share behind Chemist Warehouse

Morgans has just upgraded its rating on this ASX healthcare stock due to ongoing share price weakness.

Read more »

Woman using a pen on a digital stock market chart in an office.
Healthcare Shares

Why this ASX healthcare stock is surging while the market sinks on Middle East fears

Avita shares surge as a US government contract boosts sentiment again

Read more »

A woman sits at her computer with her hand to her mouth and a contemplative smile on her face as she reads about the performance of Allkem shares on her computer
Healthcare Shares

Should you buy Telix shares after its big US news?

Is this milestone a reason to invest? Let's find out.

Read more »

Three health professionals at a hospital smile for the camera.
Healthcare Shares

Up 31% in a month, why are Telix shares lifting off again on Friday?

ASX investors are piling into Telix shares today. But why?

Read more »

Doctor checking patient's spine x-ray image.
Healthcare Shares

Where is the value amongst ASX healthcare shares?

These three stocks are worth monitoring.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Telix Pharmaceuticals: FDA accepts Pixclara NDA

The FDA has accepted Telix's Pixclara NDA for imaging brain cancer.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Bell Potter says this ASX healthcare stock could rise nearly 200%

The positive announcement has reinforced the broker's recommendation.

Read more »

A man rests his chin in his hands, pondering what is the answer?
Healthcare Shares

CSL shares: 3 reasons to buy and 3 reasons to sell

CSL shares have tumbled again.

Read more »